This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Broad Institute's CRISPR patent invalidated by JPO over priority rights

By Toko Sekiguchi ( April 16, 2025, 08:30 GMT | Insight) -- South Korean biotech company ToolGen has won a patent-invalidation case in Japan, where Japan’s patent office invalidated a genome-engineering technology patent held by The Broad Institute, the Massachusetts Institute of Technology and Harvard College over the legitimacy of priority-rights transfer. The decision is now being appealed to Japan’s Intellectual Property High Court by the respondents.South Korean biotech company ToolGen has won a patent-invalidation case in Japan, where Japan’s patent office invalidated a genome-engineering technology patent held by The Broad Institute, the Massachusetts Institute of Technology and Harvard College over the legitimacy of priority-rights transfer. The decision is now being appealed to Japan’s Intellectual Property High Court by the respondents....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections